A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention.
Alcohol Alcohol
; 35(4): 319-23, 2000.
Article
en En
| MEDLINE
| ID: mdl-10905994
ABSTRACT
In the human central nervous system, the gamma-aminobutyric acid (GABA) type A receptor complex undergoes changes with both acute and chronic exposure to sedative-hypnotic drugs. These changes contribute to both the acute effects of these drugs as well as the chronic effects of sedative-hypnotic dependence, withdrawal, and drug craving. Clinically these chronic effects are difficult to treat in patients dependent on ethanol or benzodiazepines. Valproate may return the GABA type A receptor function to a state more closely resembling its normal function. By this mechanism, it is possible to reduce the symptoms of sedative-hypnotic withdrawal and relapse.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Síndrome de Abstinencia a Sustancias
/
Ácido Valproico
/
GABAérgicos
/
Hipnóticos y Sedantes
Límite:
Humans
Idioma:
En
Revista:
Alcohol Alcohol
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos